ENB-105 is under development for the treatment of inflammatory bowel disease and immune checkpoint inhibitor colitis (ICI-Colitis). It is being developed based on eSTEM systems biology platform.

AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Neuroendocrine Tumors.

Detailed price information for Troilus Gold Corp (TLG-T) from The Globe and Mail including charting and trades.

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Pharmaceutical and biotech stocks may find it tough to outperform the market in the months ahead. That is the view of UBS ...

Signals from the incoming administration indicate a possible focus on policy pivots that they believe will result in a more ...

As 2024 ends, India’s AI sector has transitioned from its experimentation stage to strategic adoption, primarily driven by ...

The war between Russia and Ukraine has now entered its 1044th day since starting on February 24, 2022. In this relatively short time, drones have become a bona fide tour de force on the battlefield.

Northwestern this fall will become the newest site for Bottom Line, a nonprofit initiative that gives students from ...

Struggling with automated bidding on Google Ads? Learn practical insights to improve campaign performance and control costs.

Calling 2024 “a year of transition,” Councilman and 2024 Mayor Pro-Tem Justin Wright said the city saw transitions in staffing and leadership. Mike Brumfield, the city’s director of operations, ...

Troilus Gold Corp. ("Troilus" or the "Company"), is pleased to provide a recap of its 2024 milestones and share its outlook for 2025 as it builds on exploration successes and transitions from resource ...